Hospital Denial Management: Prioritize High-Value Claims Before Submission

Hospital revenue cycle teams often track denials by volume, payer, reason code, and aging. But effective denial management services should also account for another dimension: how much reimbursement is at risk when a claim is denied.

The Agency for Healthcare Research and Quality's (AHRQ) latest analysis of high-cost inpatient conditions offers a useful framework for denial management in billing. Twenty conditions accounted for 46.8% of aggregate U.S. inpatient hospital costs in 2022, with septicemia alone accounting for $60 billion [1].

The lesson for revenue cycle leaders is not simply to prioritize the most expensive diagnoses nationally. AHRQ's figures measure hospital production costs, not reimbursement or denied dollars. Instead, hospitals can apply the same concentration principle to their own data: identify where high claim values, high denial rates, recurring payer issues, and long resolution times intersect.

That is where denial prevention efforts may protect the greatest amount of reimbursement.

Key Takeaway: Denial volume tells a hospital how often revenue is being disrupted. Financial exposure shows where that disruption matters most. Effective healthcare denial management should account for both.

The AHRQ report provides hospital revenue cycle leaders evaluating denial management services with a detailed map of where inpatient costs are concentrated [1]. 

In February 2026, AHRQ published a statistical brief built on the 2022 HCUP National Inpatient Sample, which covers stays at nonfederal acute care hospitals nationwide. Researchers converted billed charges to production costs with HCUP cost-to-charge ratios. The figures measure what hospitals spent to deliver care and do not cover payer reimbursement and separately billed physician fees. 

The sample covers 32.9 million stays and $548.5 billion in aggregate hospital costs. Twenty conditions accounted for 46.8% of aggregate hospital costs and 43.1% of all inpatient stays. Septicemia led at $60.0 billion, or 10.9% of all costs. Liveborn infants ($19.6 billion), heart failure ($18.2 billion), acute myocardial infarction ($16.3 billion), and COVID-19 ($16.0 billion) rounded out the top five. Teams should weigh the COVID-19 figures against their current census, since 2022 volumes reflect an earlier stage of the pandemic.

From a payer angle, government programs carried most of the load. Medicare and Medicaid together made up 67.3% of aggregate costs. Septicemia ranked first for all four payer groups. Seven conditions appeared on every payer's top 20: septicemia, heart failure, acute myocardial infarction, COVID-19, diabetes with complications, cerebral infarction, and respiratory failure.

Rather than treating the national ranking as a denial priority list, hospitals can use it as a starting point for deciding where to examine their own denial exposure.

These differences reinforce why hospitals should not use a single organization-wide priority list for high-value denials. National cost data can indicate where to investigate, but denial priorities should ultimately reflect each hospital's own payer mix, claim values, denial rates, and root-cause patterns.

• Medicare: Review recurring medical necessity, clinical validation, coding, and device-related denials.
• Medicaid: Strengthen eligibility, newborn enrollment, authorization, and state-specific requirement checks upstream.
• Private insurance: Focus on authorization, payer medical policies, and clinical validation criteria before high-value claims are released.
• Accounts at risk of becoming self-pay: Prioritize coverage discovery, Medicaid eligibility screening, and financial clearance before the account moves downstream.

For Medicaid and accounts at risk of becoming self-pay, many preventable revenue issues begin at registration, where everyday front-end errors can create avoidable downstream exposure.

Hospitals should not rank denial priorities by volume alone. Combining claim value, denial frequency, payer, root cause, recoverability, and time to resolution provides a clearer view of where prevention efforts can have the greatest financial impact.

The AHRQ brief tracks cost but hospitals can lay their own denial data over the same framework, whether they manage denials in-house or through denial management services. 

The goal is to identify where high-value claims and recurring denial patterns intersect. A denial on a high-value septicemia, cardiac, or surgical stay can place substantially more reimbursement at risk than a denial on a lower-value encounter, increasing the financial impact of delayed or lost payment.

For most revenue cycle teams, sepsis may be one useful area to examine. AHRQ's septicemia category counts all sepsis infection codes without requiring organ dysfunction. Some private payers apply the narrower Sepsis-3 definition during clinical validation, and Sepsis-3 requires evidence of organ dysfunction. Research in Critical Care Explorations found that this gap between definitions can lead to denied payments and overpayment requests. Effective denial management in billing for sepsis starts with physician documentation that names the organ dysfunction and ties it to the infection [2].

For hospitals seeing recurring sepsis denials, prevention should begin with documentation and clinical validation. Physician documentation should clearly identify the organ dysfunction involved and establish its relationship to the infection where required to support the diagnosis.

From there, hospitals can mirror the AHRQ structure internally. Rank high-value conditions or service lines by payer, then add the operational data that determines actual denial exposure.

A high-value denial report should include:

• Claim value or reimbursement at risk
• Denial rate
• Denial volume
• Leading denial reason
• Payer
• Service line or diagnosis
• Days to resolution
• Appeal success or overturn rate
• Recurring root cause

This turns hospital denial management into a prioritization model based on dollars at risk rather than aging or volume alone.

A high-cost condition should not automatically move to the top of the denial work queue. Hospitals should evaluate four factors together:

• Financial Exposure: How much reimbursement is tied to the affected claims? High-dollar exposure increases the financial consequence of repeated denial patterns.
• Denial Frequency: How often does the problem occur? A moderate-value denial that repeats hundreds of times may warrant more intervention than an isolated high-dollar denial.
• Recoverability: How often are the denials ultimately paid, overturned, or written off? Low recoverability may indicate that greater effort should move upstream toward prevention.
• Recurrence: Is the same root cause repeating across a payer, provider, diagnosis, service line, or facility? Recurring errors create the strongest opportunity for process correction.

The highest-priority opportunities are typically those where significant financial exposure and recurring denial volume intersect with a preventable upstream root cause.

Hospitals should track high-value denials by payer, service line or diagnosis, claim value, denial rate, denial reason, days to resolution, appeal outcome, and recurring root cause.

These metrics answer different questions. Denial rate shows frequency. Claim value shows financial exposure. Days to resolution shows cash-flow impact. Appeal outcome indicates recoverability. Root-cause tracking identifies whether the same issue can be eliminated upstream.

Together, they provide a stronger basis for deciding which denial patterns deserve immediate operational intervention.

Much of a claim's payment risk is created before the claim is ever submitted. Eligibility, authorization, documentation, coding, clinical validation, and payer-specific requirements can determine whether a high-value claim moves cleanly toward payment or enters a denial-and-appeal cycle.

3Gen Consulting's approach to healthcare denial management prioritizes prevention alongside recovery. For high-value inpatient claims, three functions are particularly important:

1. Pre-Bill Validation

Review coding, clinical documentation, authorization, medical necessity, and payer-specific requirements before the claim is released.

2. Pattern Tracking

Group denials by payer, diagnosis or service line, denial reason, and financial exposure so recurring problems become visible before they scale.

3. Root-Cause Elimination

Route findings back to patient access, CDI, coding, billing, and clinical teams so the same error does not continue cycling through the appeals process.

Our breakdown of denial prevention versus denial management covers the distinction between upstream prevention and downstream recovery in more detail.

Hospitals evaluating denial management services should look beyond appeals volume and recovery activity. A strong partner should be able to identify where denials originate, quantify financial exposure, recognize payer-specific patterns, and feed those findings back into upstream workflows.

Medical billing companies with inpatient revenue cycle experience should be able to support both the data and operational sides of denial prevention – including payer and diagnosis analysis, clinical documentation review, coding validation, workflow redesign, and staff education where recurring issues are identified.

3Gen Consulting supports hospitals and health systems across denial prevention and recovery by combining payer-specific analysis, clinical and coding expertise, and root-cause workflows designed to reduce repeat denials rather than simply work them after they occur.

Whether you are strengthening an internal denial management program or evaluating external support, the objective should remain the same: identify where reimbursement is most exposed, intervene before preventable denials occur, and focus recovery resources on true exceptions.

Talk to 3Gen about your denial management priorities.